Literature DB >> 30925850

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.

James Fadiman1, Sophia Korb2.   

Abstract

Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration of the effects of "microdoses," comprising hundreds of lengthy descriptive reports, was undertaken. Based on these reports, using a psychedelic in the microdose range (10 micrograms) every three days was determined to be safe across a wide variety of individuals and conditions. Over 18 months, more than a thousand individuals from 59 countries did a daily evaluation of negative and positive emotional state using the PANAS checklist plus written reports for between one week and four months. Participant reports suggested that spaced but repeated microdoses were followed by improvements in negative moods, especially depression, and increases in positive moods. Increased energy, improved work effectiveness, and improved health habits were observed in clinical and non-clinical populations. Smaller samples described alleviation of symptoms in migraine headaches, pre-menstrual syndromes, traumatic brain injury, shingles, and other conditions not previously associated with psychedelic use.

Entities:  

Keywords:  LSD; Psychedelics; microdosing; psilocybin

Mesh:

Substances:

Year:  2019        PMID: 30925850     DOI: 10.1080/02791072.2019.1593561

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  19 in total

1.  Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.

Authors:  Anya K Bershad; Katrin H Preller; Royce Lee; Sarah Keedy; Jamie Wren-Jarvis; Michael P Bremmer; Harriet de Wit
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-20

2.  Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.

Authors:  Conor H Murray; Ilaria Tare; Claire M Perry; Michael Malina; Royce Lee; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2021-10-06       Impact factor: 4.530

3.  Natural language signatures of psilocybin microdosing.

Authors:  Camila Sanz; Federico Cavanna; Stephanie Muller; Laura de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar; Facundo Carrillo; Adolfo M García; Carla Pallavicini; Enzo Tagliazucchi
Journal:  Psychopharmacology (Berl)       Date:  2022-06-09       Impact factor: 4.415

4.  Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Authors:  Joseph M Rootman; Maggie Kiraga; Pamela Kryskow; Kalin Harvey; Paul Stamets; Eesmyal Santos-Brault; Kim P C Kuypers; Zach Walsh
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

5.  Dosing Psychedelics and MDMA.

Authors:  Matthias E Liechti; Friederike Holze
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  Psychedelic Microdosing: Prevalence and Subjective Effects.

Authors:  Lindsay P Cameron; Angela Nazarian; David E Olson
Journal:  J Psychoactive Drugs       Date:  2020-01-23

7.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Authors:  Kim Pc Kuypers; Livia Ng; David Erritzoe; Gitte M Knudsen; Charles D Nichols; David E Nichols; Luca Pani; Anaïs Soula; David Nutt
Journal:  J Psychopharmacol       Date:  2019-07-14       Impact factor: 4.153

8.  Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers.

Authors:  Nadia R P W Hutten; Natasha L Mason; Patrick C Dolder; Kim P C Kuypers
Journal:  Front Psychiatry       Date:  2019-09-13       Impact factor: 4.157

9.  Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube.

Authors:  Martin Andersson; Anette Kjellgren
Journal:  Harm Reduct J       Date:  2019-11-28

10.  Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.

Authors:  Kate Corrigan; Maeve Haran; Conor McCandliss; Roisin McManus; Shannon Cleary; Rebecca Trant; Yazeed Kelly; Kathryn Ledden; Gavin Rush; Veronica O'Keane; John R Kelly
Journal:  Ir J Med Sci       Date:  2021-06-15       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.